Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Share-based Compensation (2022 - 2025)

Prokidney (PROK) has disclosed Share-based Compensation for 4 consecutive years, with $5.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 93.36% to $5.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.3 million, a 26.69% increase, with the full-year FY2024 number at $24.5 million, down 20.54% from a year prior.
  • Share-based Compensation was $5.9 million for Q3 2025 at Prokidney, up from $5.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $52.7 million in Q1 2022 to a low of $1.5 million in Q4 2023.
  • A 4-year average of $9.9 million and a median of $6.0 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 83.47% in 2023, then soared 302.57% in 2024.
  • Prokidney's Share-based Compensation stood at $8.9 million in 2022, then tumbled by 83.47% to $1.5 million in 2023, then surged by 302.57% to $5.9 million in 2024, then decreased by 0.24% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Share-based Compensation are $5.9 million (Q3 2025), $5.0 million (Q2 2025), and $6.4 million (Q1 2025).